Efficacy and safety of Xa inhibitors in patients with heart failure and coronary or peripheral artery disease: a systematic review and meta-analysis of randomized controlled trials.
Sign Up to like & getrecommendations! Published in 2021 at "Annals of palliative medicine"
DOI: 10.21037/apm-21-1645
Abstract: BACKGROUND To evaluate the efficacy and safety of Xa inhibitors in patients with heart failure (HF) and coronary artery disease (CAD) or peripheral artery disease (PAD). METHODS A systematic electronic literature search was performed using… read more here.
Keywords: control group; artery disease; group; rivaroxaban group ... See more keywords
A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2022.803233
Abstract: Objective To compare the clinical benefits of rivaroxaban and warfarin in patients with non-valvular atrial fibrillation (NVAF) with high bleeding risk. Methods A retrospective study was conducted on patients with high bleeding risk NVAF who… read more here.
Keywords: group; bleeding risk; clinical benefits; rivaroxaban group ... See more keywords
A comparative study of the clinical benefits of rivaroxaban and dabigatran in patients with nonvalvular atrial fibrillation with high bleeding risk
Sign Up to like & getrecommendations! Published in 2024 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2024.1445970
Abstract: Objective Rivaroxaban and dabigatran are approved to reduce the risk of stroke in patients with nonvalvular atrial fibrillation (NVAF). However, the clinical benefits of rivaroxaban and dabigatran in people with high bleeding risk are unclear.… read more here.
Keywords: bleeding risk; risk; group; rivaroxaban group ... See more keywords